4:23 PM
 | 
Oct 19, 2018
 |  BioCentury  |  Finance

CuraSen’s SPARK

How neurodegenerative disease play CuraSen plans to deploy its $54.5M series A

After debuting with a $54.5 million series A round, CuraSen Therapeutics Inc. hopes to generate clinical proof-of-concept data for at least two neurodegenerative disease programs in the next three years.

New Leaf Venture Partners led the round, which closed on Oct. 17. Funds managed by Tekla Capital, Alta Partners, Johnson & Johnson Innovation - JJDC Inc. and Pappas Capital also participated.

CuraSen emerged from Stanford University’s SPARK program and...

Read the full 324 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >